Sirtex profits up eightfold
Friday, 28 August, 2009
Medical device company, Sirtex, best known for its anti-cancer SIR-Spheres, has announced an impressive boost in revenues of 72 per cent over the past financial year.
In an ASX announcement, the company has indicated a 42 per cent increase in sales of its flagship product, leading to a net profit before tax of $23 million, up from $2.5 million the previous financial year.
SIR-Spheres experienced growth in all markets, up 28 per cent in the US, 117 per cent in Europe and 17 per cent in Asia Pacific.
In today's trading, Sirtex (ASX:SRX) was up 7.7% to $4.64.
TGA acts on melatonin imports with infringement notices totalling $99K
Laboratory testing of several imported unregistered melatonin products has confirmed them to be...
Scientists search for cystitis pain 'off switch'
By targeting certain pain receptors in the bladder, Australian scientists believe that the...
Australia's first cases of H5 avian influenza confirmed
Positive results for H5 avian influenza (bird flu) have been confirmed in two seabirds found in...
